AR032781A1 - Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen - Google Patents
Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienenInfo
- Publication number
- AR032781A1 AR032781A1 ARP010105720A ARP010105720A AR032781A1 AR 032781 A1 AR032781 A1 AR 032781A1 AR P010105720 A ARP010105720 A AR P010105720A AR P010105720 A ARP010105720 A AR P010105720A AR 032781 A1 AR032781 A1 AR 032781A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- conh2
- coome
- methylsulfonylamino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 OR15 Chemical group 0.000 abstract 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 14
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 125000002541 furyl group Chemical group 0.000 abstract 4
- 125000001624 naphthyl group Chemical group 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 4
- 125000001544 thienyl group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 2
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Chemical group 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 230000001746 atrial effect Effects 0.000 abstract 2
- 239000004305 biphenyl Chemical group 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical group F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 2
- 125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
- 206010003662 Atrial flutter Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical class OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Amidas ariladas de ácidos fura- y tiofencarboxílicos, que comprenden compuestos de las formula (1) y (2), donde X representa oxígeno o azufre; R1 representa C(O)OR9, SO2R10, COR11, C(O)NR12R13 o C(S)NR12R13; R9, R10, R11 y R12, independientemente entre sí, representan CxH2x-R14; x representa 0, 1, 2, 3 o 4; no pudiendo x ser igual a cero cuando R14 representa OR15 o SO2Me; R14 representa alquilo C1-6, cicloalquilo C3-10, CF3, C2F5, C3F7, CH2F, CHF2, OR15, SO2Me, fenilo, naftilo, bifenilo, furilo, tienilo o un heteroaromato que contiene nitrogeno C1-9; pudiendo fenilo, naftilo, bifenilo, furilo, tienilo y el heteroaromato que contiene nitrogeno, estar sin sustituir o estar sustituido con 1, 2 o 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metilsulfonilamino; R15 representa alquilo C1-5, cicloalquilo C3-5, CF3 o fenilo, que está sin sustituir o está sustituido con 1, 2 o 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metilsulfonilamino; R13 representa hidrogeno, alquilo C1-4 o CF3, R2 representa hidrogeno, alquilo C1-4 o CF3; R3 representa CyH2y-R16; y representa 0, 1, 2, 3 o 4; no pudiendo y ser igual a 0 cuando R16 representa OR17 o SO2Me; R16 representa alquilo C1-6, cicloalquilo C3-11, CF3, C2F5, C3F7, CH2F, CHF2, OR17, SO2Me, fenilo, naftilo, furilo, tienilo o un heteroaromato que contiene nitrogeno C1-9; estando fenilo, naftilo, furilo, tienilo y el heteroaromato que contiene nitrogeno, sin sustituir o está sustituido con 1, 2 o 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-6, dimetilamino, sulfamoílo, metil sulfonilo y metilsulfonilamino; R17 representa hidrogeno, alquilo C1-5, cicloalqulo C3-6, CF3, fenilo o 2-, 3- o 4-piridilo; estando fenilo o 2-, 3- o 4-piridilo, sin sustituir o está sustituido con 1, 2 o 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metilsulfonilamino;o R3 representa CHR18R19; R18 representa hidrogeno o CzH2z-R16, siendo R16 como anteriormente mencionado, z vale 0, 1, 2 o 3; R19 representa COOH, CONH2, CONR20R21 o CH2OH; R20 representa hidrogeno, alquilo C1-5, CvH2v-CF3 o CwH2w-fenilo; estando el anillo fenilo, sin sustituir o está sustituido con 1, 2 o 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metilsulfonilamino; v vale 0, 1, 2 o 3; w vale 0, 1, 2 o 3; R21 representa hidrogeno o alquilo C1-5; R22 representa alquilo C1-5; R4 representa hidrogeno, alquilo C1-6 o CF3; R3 y R4 representan conjuntamente una cadena de 4 o 5 grupos metileno, de los cuales un grupo metileno puede estar sustituido por -O-, -S-, -NH-, N(metil)- o -N(bencil)-; R5, R6, R7, independientemente entre sí, representan F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo o metilsulfonilamino; R30 y R31, independientemente entre sí representan hidrogeno o alquilo C1-3; o: R30 y R31, independientemente entre sí, representan oxígeno o una cadena de 2 grupos metileno; como también sus sales farmacéuticamente aceptables, que son muy especialmente adecuados como novedosas sustancias activas como antiarrítmicas, en especial para el tratamiento y profilaxis de las arritmias auriculares, por ejemplo la fibrilacion auricular (atrial Fibrillation, AF) o el aleteo o fluter auricular (atriales Flattern). También se describen composiciones farmacéuticas y el uso de dichas amidas para la preparacion de medicamentos para el tratamiento y profilaxis de las arritmias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10061876A DE10061876A1 (de) | 2000-12-12 | 2000-12-12 | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032781A1 true AR032781A1 (es) | 2003-11-26 |
Family
ID=7666837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105720A AR032781A1 (es) | 2000-12-12 | 2001-12-10 | Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6982279B2 (es) |
| EP (1) | EP1349846B1 (es) |
| JP (1) | JP4252798B2 (es) |
| KR (1) | KR20030061846A (es) |
| CN (1) | CN1225463C (es) |
| AR (1) | AR032781A1 (es) |
| AT (1) | ATE288906T1 (es) |
| AU (2) | AU3574302A (es) |
| BR (1) | BR0116084A (es) |
| CA (1) | CA2431095A1 (es) |
| CZ (1) | CZ20031633A3 (es) |
| DE (2) | DE10061876A1 (es) |
| DK (1) | DK1349846T3 (es) |
| EE (1) | EE05306B1 (es) |
| ES (1) | ES2236335T3 (es) |
| HR (1) | HRP20030469A2 (es) |
| HU (1) | HUP0303665A3 (es) |
| IL (2) | IL156314A0 (es) |
| MX (1) | MXPA03004770A (es) |
| NO (1) | NO329163B1 (es) |
| NZ (1) | NZ526383A (es) |
| PL (1) | PL362410A1 (es) |
| PT (1) | PT1349846E (es) |
| RS (1) | RS50336B (es) |
| RU (1) | RU2275366C2 (es) |
| SK (1) | SK287464B6 (es) |
| TW (1) | TWI288134B (es) |
| WO (1) | WO2002048131A1 (es) |
| ZA (1) | ZA200304091B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| PT1401825E (pt) * | 2001-06-11 | 2009-10-23 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus |
| CN100413861C (zh) | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
| GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
| EP1493739A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
| BRPI0610283A2 (pt) * | 2005-05-13 | 2010-10-19 | Virochem Pharma Inc | composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica |
| JP4943429B2 (ja) * | 2005-07-22 | 2012-05-30 | メルク・シャープ・エンド・ドーム・コーポレイション | カリウムチャネル阻害剤 |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| CA2650391C (en) * | 2006-04-27 | 2015-12-15 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the task-1 and task-3 ion channel |
| SG176488A1 (en) | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| KR101257550B1 (ko) | 2007-09-10 | 2013-04-24 | 칼시메디카, 인크 | 세포내 칼슘을 조절하는 화합물 |
| ITMI20071971A1 (it) * | 2007-10-10 | 2009-04-11 | Altergon Sa | Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione |
| WO2009076454A2 (en) | 2007-12-12 | 2009-06-18 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN102256969A (zh) | 2008-08-27 | 2011-11-23 | 钙医学公司 | 调节胞内钙的化合物 |
| GB0815784D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815782D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815781D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| UA106740C2 (uk) * | 2009-01-30 | 2014-10-10 | Глаксосмітклайн Ллс | Кристалічний гідрохлорид n-{(1s)-2-аміно-1-[(3-фторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1h-піразол-5-іл)-2-тіофенкарбоксаміду |
| WO2011034962A2 (en) | 2009-09-16 | 2011-03-24 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| AU2011265047B2 (en) | 2010-06-07 | 2014-10-23 | Novomedix, Llc | Furanyl compounds and the use thereof |
| US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| AU2013203252B2 (en) | 2012-01-27 | 2015-08-20 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN103012381B (zh) * | 2013-01-10 | 2015-01-07 | 山东大学 | 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用 |
| KR101721490B1 (ko) * | 2014-07-30 | 2017-03-30 | 한국생명공학연구원 | 페닐 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 세포증식성 질병의 예방 또는 치료용 약학적 조성물 |
| EP3366683A1 (en) * | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9214120D0 (en) * | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
| DK41193D0 (da) * | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4412334A1 (de) * | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US5670504A (en) | 1995-02-23 | 1997-09-23 | Merck & Co. Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
| US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| US5935945A (en) | 1996-10-31 | 1999-08-10 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| US5969017A (en) | 1996-10-31 | 1999-10-19 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| US6013664A (en) * | 1996-11-27 | 2000-01-11 | Bayer Aktiengesellschaft | Microbicidal agents based on thiophene-2-carboxylic acid derivatives |
| WO1999007670A1 (en) * | 1997-08-05 | 1999-02-18 | American Home Products Corporation | Anthranilic acid analogs |
| DK1040108T3 (da) * | 1997-12-19 | 2004-05-24 | Schering Ag | Orthoanthranilamidderivater som antikoagulanter |
| US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
| KR20010082515A (ko) * | 1998-02-17 | 2001-08-30 | 우에노 도시오 | 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제 |
| EP0960882A1 (en) * | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| WO1999062891A1 (en) | 1998-06-05 | 1999-12-09 | Icagen, Inc. | Potassium channel inhibitors |
| CA2341678C (en) | 1998-09-01 | 2009-10-13 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
| AU5379900A (en) * | 1999-06-07 | 2000-12-28 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| US6562816B2 (en) * | 2001-08-24 | 2003-05-13 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
-
2000
- 2000-12-12 DE DE10061876A patent/DE10061876A1/de not_active Withdrawn
-
2001
- 2001-11-29 DE DE50105337T patent/DE50105337D1/de not_active Expired - Lifetime
- 2001-11-29 HR HR20030469A patent/HRP20030469A2/hr not_active Application Discontinuation
- 2001-11-29 AU AU3574302A patent/AU3574302A/xx active Pending
- 2001-11-29 BR BR0116084-2A patent/BR0116084A/pt not_active Application Discontinuation
- 2001-11-29 RU RU2003121236/04A patent/RU2275366C2/ru not_active IP Right Cessation
- 2001-11-29 NZ NZ526383A patent/NZ526383A/en unknown
- 2001-11-29 PL PL01362410A patent/PL362410A1/xx not_active IP Right Cessation
- 2001-11-29 EE EEP200300240A patent/EE05306B1/xx not_active IP Right Cessation
- 2001-11-29 RS YUP-425/03A patent/RS50336B/sr unknown
- 2001-11-29 PT PT01985832T patent/PT1349846E/pt unknown
- 2001-11-29 HU HU0303665A patent/HUP0303665A3/hu unknown
- 2001-11-29 CA CA002431095A patent/CA2431095A1/en not_active Abandoned
- 2001-11-29 CN CNB018204007A patent/CN1225463C/zh not_active Expired - Fee Related
- 2001-11-29 ES ES01985832T patent/ES2236335T3/es not_active Expired - Lifetime
- 2001-11-29 WO PCT/EP2001/013958 patent/WO2002048131A1/de not_active Ceased
- 2001-11-29 SK SK725-2003A patent/SK287464B6/sk not_active IP Right Cessation
- 2001-11-29 EP EP01985832A patent/EP1349846B1/de not_active Expired - Lifetime
- 2001-11-29 KR KR10-2003-7007875A patent/KR20030061846A/ko not_active Abandoned
- 2001-11-29 DK DK01985832T patent/DK1349846T3/da active
- 2001-11-29 IL IL15631401A patent/IL156314A0/xx unknown
- 2001-11-29 MX MXPA03004770A patent/MXPA03004770A/es active IP Right Grant
- 2001-11-29 AU AU2002235743A patent/AU2002235743B2/en not_active Ceased
- 2001-11-29 CZ CZ20031633A patent/CZ20031633A3/cs unknown
- 2001-11-29 JP JP2002549662A patent/JP4252798B2/ja not_active Expired - Fee Related
- 2001-11-29 AT AT01985832T patent/ATE288906T1/de active
- 2001-12-10 AR ARP010105720A patent/AR032781A1/es active IP Right Grant
- 2001-12-10 TW TW090130471A patent/TWI288134B/zh not_active IP Right Cessation
- 2001-12-12 US US10/012,338 patent/US6982279B2/en not_active Expired - Fee Related
-
2003
- 2003-05-27 ZA ZA200304091A patent/ZA200304091B/en unknown
- 2003-06-04 IL IL156314A patent/IL156314A/en not_active IP Right Cessation
- 2003-06-04 NO NO20032535A patent/NO329163B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032781A1 (es) | Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen | |
| AR033408A1 (es) | Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen | |
| AR031226A1 (es) | 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen | |
| AR033623A1 (es) | Amidas de acidos antranilicos, composiciones farmaceuticas que las contienen, asi como empleo para la manufactura de un medicamento | |
| AR036045A1 (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, su empleo para la preparacion de un medicamento, asi como composiciones farmaceuticas que las contienen | |
| DE60330910D1 (de) | Verbindungen mit selektiverinhibierender wirkung für gsk3 | |
| CY1110904T1 (el) | Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun | |
| RU2003120080A (ru) | Орто-замещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции | |
| HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
| AR033306A1 (es) | Compuestos | |
| ATE383339T1 (de) | Amin-derivate zur behandlung von apoptosis | |
| EA200300792A1 (ru) | Хиназолины в качестве ингибиторов ммр-13 | |
| RU2003121236A (ru) | Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием | |
| HRP20040317A2 (en) | 1,8-naphthyridine derivatives as antidiabetics | |
| NO20101069L (no) | Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva | |
| DE60218048D1 (de) | Thiophenverbindungen als arzneimittel | |
| CO5271675A1 (es) | Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen | |
| SE9701304D0 (sv) | Compounds | |
| EP1314719A4 (en) | BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT | |
| SE0201194D0 (sv) | New compounds | |
| DE60011110D1 (de) | Pharmazeutisch wirksame sulfonyl hydrazid-derivate | |
| DE60042831D1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
| UA72945C2 (uk) | Сполука (варіанти), фармацевтична композиція, спосіб лікування (варіанти) | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| ATE246177T1 (de) | Katecholhydrazon-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |